CHMP backs expanding scope of Kyowa Kirin’s Crysvita
The decision could see older adolescents and adults access the treatment for X-linked hypophosphataemia (XLH)
Read More
Tag: X-linked hypophosphataemia
XLH patients to get routine access to first new therapy in 30 years
For the first time in more than 30 years children and young adults in England and Wales with the rare bone disorder XLH will have access to a new treatment option via the NHS.
Read More
NICE u-turn approves funding for rare disease therapy Crysvita
The National Institute for Health and Care Excellence (NICE) has changed its position on NHS funding for Kyowa Kirin International’s Crysvita, now endorsing the drug’s use to treat X-linked hypophosphataemia (XLH) in children and young people with growing bones in England and Wales.
Read More
EU clears rare musculoskeletal disorder drug
Doctors can now treat children living in the EU with the rare, chronic progressive musculoskeletal disorder X–Linked Hypophosphataemia with Kyowa Kirin/Ultragenyx’ Crysvita following its conditional approval in the region.
Read More
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
